Lecanemab, an experimental Alzheimer's drug made by Eisai Co Ltd and Biogen slowed cognitive and functional decline in a large trial of patients in the early stages of the disease, reports said this week.

Some experts called it a "positive effect" and not a huge effect. Eisai is seeking FDA approval in the US under an accelerated pathway, with a decision expected in early January.

Disclaimer Statement: This content is authored by an external agency. The views expressed here are that of the respective authors/ entities and do not represent the views of Economic Times (ET). ET does not guarantee, vouch for or endorse any of its contents nor is responsible for them in any manner whatsoever. Please take all steps necessary to ascertain that any information and content provided is correct, updated, and verified. ET hereby disclaims any and all warranties, express or implied, relating to the report and any content therein.

Lecanemab: All about the Alzheimer's drug that shows promise

Clinical trials on 1800 patients with early-stage Alzheimer's has showed that Lecanemab slows the advance of the disease.

Read More News on